Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
Rhea-AI Summary
Firefly Neuroscience (NASDAQ: AIFF), an AI-driven brain health company, has announced a shareholder update call scheduled for September 4, 2024, at 5:00 PM EST. The company, which focuses on developing innovative neuroscientific solutions for mental illnesses and neurological disorders, will provide investors with the latest information about its operations and progress.
Shareholders and interested parties can register for the webinar through the provided Zoom link. This update call presents an opportunity for investors to gain insights into Firefly's advancements in AI technology applied to brain health and its potential impact on patient outcomes.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AIFF declined 3.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced management will host a shareholder update call on Wednesday, September 4, 2024 at 5:00 PM Eastern Time.
Event: Firefly Neuroscience Shareholder Update
Date: Wednesday, September 4, 2024
Time: 5:00 PM EST
Webinar Registration Link: https://us02web.zoom.us/webinar/register/WN_uUqPh-uSRhyYX0nzBrrh3w#/registration
About Firefly
Firefly (Nasdaq: AIFF) is an Artificial Intelligence (“AI”) technology company dedicated to developing groundbreaking neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) platform revolutionizes diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has invested approximately
The BNA platform is a software as a medical solution (SAMS) that was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. The BNA platform, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function (cognition). These insights can enhance a clinician’s ability to accurately diagnose mental illnesses and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
PH: (212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
FAQ
When is Firefly Neuroscience (AIFF) hosting its shareholder update call?
How can I register for Firefly Neuroscience's (AIFF) shareholder update call?
What is the main focus of Firefly Neuroscience (AIFF) as a company?
On which stock exchange is Firefly Neuroscience (AIFF) listed?
